These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26346540)

  • 21. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension.
    Guthrie RM
    Postgrad Med; 2011 Nov; 123(6):58-65. PubMed ID: 22104454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
    Hayashi M; Uchida S; Kawamura T; Kuwahara M; Nangaku M; Iino Y;
    Clin Exp Nephrol; 2015 Oct; 19(5):925-32. PubMed ID: 25680887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study).
    Motozato K; Miura S; Shiga Y; Kusumoto T; Adachi S; Inoue T; Fujisawa K; Saku K
    Clin Exp Hypertens; 2016; 38(1):45-50. PubMed ID: 26268636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current perspectives on combination therapy in the management of hypertension.
    Mallat SG; Itani HS; Tanios BY
    Integr Blood Press Control; 2013; 6():69-78. PubMed ID: 23837009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
    Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
    Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial.
    Oh GC; Lee HY; Chung WJ; Youn HJ; Cho EJ; Sung KC; Chae SC; Yoo BS; Park CG; Hong SJ; Kim YK; Hong TJ; Choi DJ; Hyun MS; Ha JW; Kim YJ; Ahn Y; Cho MC; Kim SG; Shin J; Park S; Sohn IS; Kim CJ
    Clin Hypertens; 2017; 23():18. PubMed ID: 28879040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients.
    Kim YH; Her AY; Rha SW; Choi BG; Choi SY; Byun JK; Kang DO; Jang WY; Kim W; Baek JY; Choi WG; Kang TS; Ahn J; Park SH; Park SH; Hong JY; Park JY; Lee MH; Choi CU; Park CG; Seo HS
    J Diabetes Metab Disord; 2020 Jun; 19(1):405-413. PubMed ID: 32550191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of valsartan and amlodipine on ambulatory blood pressure variability in hypertensive patients.
    Eguchi K; Imaizumi Y; Kaihara T; Hoshide S; Kario K
    Clin Exp Hypertens; 2016; 38(8):721-724. PubMed ID: 27936949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study.
    Akram J; Sheikh UE; Mahmood M; Donnelly R
    Curr Med Res Opin; 2007 Dec; 23(12):2929-36. PubMed ID: 17931463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study.
    Ahmed M; Alanbaei M; El Tamimi H; Al-Wahshi Y; Al-Zakwani I
    Curr Vasc Pharmacol; 2016; 14(6):570-575. PubMed ID: 27456109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of angiotensin receptor blocker-based combination therapy with persistence and adherence in newly treated, uncomplicated hypertensive patients.
    Ah YM; Shin J; Lee JY
    Patient Prefer Adherence; 2019; 13():241-248. PubMed ID: 30774320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home.
    Hashimoto J; Hirayama H; Hanasawa T; Watabe D; Asayama K; Metoki H; Kikuya M; Ohkubo T; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 May; 27(4):331-41. PubMed ID: 15921070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diuretic or Beta-Blocker for Hypertensive Patients Already Receiving ACEI/ARB and Calcium Channel Blocker.
    Tsai MS; Tang CH; Lin CY; Chuang PY; Chen NC; Huang CH; Chang WT; Wang TD; Yu PH; Chen WJ
    Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):535-543. PubMed ID: 29218625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
    Chazova IE; Martynyuk TV
    Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.